• Publications
  • Influence
Secukinumab in plaque psoriasis--results of two phase 3 trials.
BACKGROUND Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients withExpand
  • 1,183
  • 54
  • PDF
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In this first of 5 sections of theExpand
  • 1,063
  • 54
  • PDF
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.
Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In this fourth of 6 sections of theExpand
  • 473
  • 32
  • PDF
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
BACKGROUND Early clinical studies suggested that the anti-interleukin-17 receptor A monoclonal antibody brodalumab has efficacy in the treatment of psoriasis. METHODS In two phase 3 studiesExpand
  • 430
  • 28
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
BACKGROUND Ixekizumab is a humanised monoclonal antibody against the proinflammatory cytokine interleukin 17A. We report two studies of ixekizumab compared with placebo or etanercept to assess theExpand
  • 547
  • 27
The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey.
BACKGROUND Psoriasis can have a profound impact on a patient's quality of life. OBJECTIVES To assess patients' perspectives on the impact of psoriasis on their lifestyle and emotional well-beingExpand
  • 938
  • 24
  • PDF
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and
Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In the first 5 parts of the AmericanExpand
  • 477
  • 24
Psoriasis
Physician Writers Rita V. Patel, MD Mark Lebwohl, MD The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), includingExpand
  • 391
  • 23
  • PDF
Ingenol mebutate gel for actinic keratosis.
BACKGROUND Actinic keratosis is a common precursor to sun-related squamous-cell carcinoma. Treating actinic keratoses and the surrounding skin area (i.e., field therapy) can eradicate clinical andExpand
  • 370
  • 21
  • PDF
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In this second of 5 sections of theExpand
  • 713
  • 16
  • PDF